SecBot SecBot
PRESS-RELEASE ·Filed Apr 23, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The FDA's approval to expand the trial strengthens Alpha Tau's clinical development path for Alpha DaRT in pancreatic cancer, one of the deadliest solid tumors. While no efficacy data is reported, the green light to test across both standard-of-care regimens de-risks future commercialization and supports potential broader label claims. Monitor for interim safety and response data in late 2026.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.98
T+0 close · Apr 23, 2026 · via day close
Latest settled
+68.80%
T+60 · $13.47
Vs SPY
+63.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $7.98entry
  2. T+1 · 7mo ago +1.38%α +0.59% · $8.09
  3. T+5 · 7mo ago −7.64%α −9.12% · $7.37
  4. T+20 · 6mo ago +40.10%α +35.47% · $11.18
  5. T+60 · 4mo ago +68.80%α +63.78% · $13.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT pilot trial for pancreatic cancer to include 10 additional patients receiving gemcitabine/nab-paclitaxel chemotherapy, increasing total enrollment from 30 to 40. The expansion allows evaluation of Alpha DaRT in combination with both major first-line chemotherapies, broadening the potential development path for this investigational therapy in a high-unmet-need population.

Key Facts

  • FDA approved an IDE supplement to expand the IMPACT trial from 30 to 40 patients
  • Expansion includes 10 new patients receiving gemcitabine/nab-paclitaxel alongside Alpha DaRT
  • Trial now covers both major first-line chemotherapies: mFOLFIRINOX and gemcitabine/nab-paclitaxel
  • Patient recruitment now expected to complete in Q3 2026, delayed from Q2 2026
  • Primary endpoints are safety, feasibility, and tolerability of Alpha DaRT implantation

Financial Impact

No direct financial impact disclosed; trial expansion may increase R&D spend modestly

R&D expenseclinical timelineregulatory risk

Risk Factors

  • Clinical trial may fail to demonstrate safety or efficacy despite regulatory allowance
  • Delayed patient recruitment pushes data readout timeline into late 2026 or 2027
  • Alpha Tau remains pre-revenue with history of losses and dependence on future funding

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3280027

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026